Literature DB >> 1643639

Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation.

J Wang1, K A Biedermann, J M Brown.   

Abstract

3-Amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) is a bioreductive anticancer drug which has a high selective toxicity to hypoxic cells. We have characterized the DNA and chromosome damage in wild-type Chinese hamster ovary (CHO) cells and mutant XR-1 cells after exposure to SR 4233 under hypoxia and compared it to the damage produced by ionizing radiation (gamma-rays). Using the technique of pulsed field gel electrophoresis, we found that the kinetics of rejoining of DNA double-strand breaks in CHO cells after treatment with SR 4233 was concentration dependent, varying from 95% (less than 50 microM) to 10% (200 microM) by 24 h. This contrasted with the dose-independent kinetics exhibited in cells after gamma-ray exposure. XR-1 cells were deficient in rejoining double-strand breaks produced by either SR 4233 or gamma-rays. XR-1 cells were 2-fold more sensitive than wild-type CHO cells to SR 4233 but were 10-fold more sensitive than CHO to gamma-rays. These results suggested that DNA double-strand breaks are involved in hypoxic cell killing by SR 4233, but the specific type of lesion produced is not identical with that causing cell killing by gamma-rays. To further investigate this, we measured chromosome breaks in CHO cells by premature chromosome condensation after equitoxic doses of SR 4233 under hypoxia and gamma-rays. SR 4233 produced lower initial but similar final (after 6 h of repair) numbers of chromosome breaks compared to gamma-rays at equitoxic doses. These results suggest that, at low doses, chromosome breaks can entirely account for hypoxic cell killing by SR 4233 and that chromosome breaks produced by SR 4233 are more damaging and/or more difficult to repair than those produced by gamma-rays.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643639

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.

Authors:  Venkatraman Junnotula; Anuruddha Rajapakse; Leire Arbillaga; Adela López de Cerain; Beatriz Solano; Raquel Villar; Antonio Monge; Kent S Gates
Journal:  Bioorg Med Chem       Date:  2010-03-19       Impact factor: 3.641

2.  Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.

Authors:  Michael P Hay; Kevin O Hicks; Karin Pchalek; Ho H Lee; Adrian Blaser; Frederik B Pruijn; Robert F Anderson; Sujata S Shinde; William R Wilson; William A Denny
Journal:  J Med Chem       Date:  2008-10-11       Impact factor: 7.446

Review 3.  Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.

Authors:  A M Mfuh; O V Larionov
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 4.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

5.  Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.

Authors:  Yvette M Delahoussaye; Michael P Hay; Frederik B Pruijn; William A Denny; J Martin Brown
Journal:  Biochem Pharmacol       Date:  2003-06-01       Impact factor: 5.858

6.  Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.

Authors:  P Wardman; K I Priyadarsini; M F Dennis; S A Everett; M A Naylor; K B Patel; I J Stratford; M R Stratford; M Tracy
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 7.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

8.  Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

Authors:  J Wang; K A Biedermann; C R Wolf; J M Brown
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

9.  Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.

Authors:  J M Silva; P J O'Brien
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

Review 10.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.